hjg123
Posted - 3 hours ago
$ATXI come on, early Christmas present would be great thanks.
MarketMindsetWOW
Posted - 1 day ago
$ATXI $NVFY LFG, expected this to move higher. Also, your thoughts on MYNZ? Who's behind the 30M share offering deal? 👀 And how could the Thermo Fisher (TMO) partnership ($210B market cap) reflect this stock movement and PR buzz everywhere on socials?
flyinghollaender
Posted - 3 days ago
$FBIO $DERM $CKPT $MBIO $ATXI
Zellchair
Posted - 3 days ago
$FBIO Are these updates enough since they initiated the PT $24 analysis for the first time? FBIO - New favorable loan deal with Oaktree - FBIO holdings in several core subsidaries increased last quarter - More insider buying $DERM - Emrosi FDA approval $CKPT - Cosibelimab BLA approved - Positive update on Cosibelimab long-term results in cSCC at ESMO - CKPT temporarily stable economic situation given the warrants $MBIO - MB-106 fantastic P1/2 results in WM . MB-108 Granted Orphan Drug Designation $ATXI - AJ201 1b/2 study completed From unlisted subsidaries - Confirmation of CUTX-101 NDA application - Extended studies for CAEL-101 - CAEL-101 P3a/b starts - Urica's deal with Crystalys regarding Dotinurad - Triplex P2 start in Liver transplantation Milestones drawn from the head quickly, must have missed a lot.
AZOZ
Posted - 5 days ago
$ATXI buy /sell ratio for today ✅
stockinvestbull
Posted - 5 days ago
$ATXI Volume comes in, upside potential. 📈
AZOZ
Posted - 5 days ago
$ATXI red to green move
Catalyst ahead!
fortyfivezZ
Posted - 6 days ago
$ATXI last rs we were at 9+? Look where we are now.
Newtothisting
Posted - 6 days ago
$ATXI penny land and rs soon
fortyfivezZ
Posted - 6 days ago
$ATXI I don't see how this can recover. Will probably be taking the L
Bangra
Posted - 6 days ago
$ATXI I have lost faith in this company. Money down the drain.
_Mateo_Bond_
Posted - 6 days ago
MYNZ looks good , added 25K shares. $ATXI $AMZN
Cats_and_Roses
Posted - 6 days ago
$ATXI unfortunately dilution is inevitable. also, data delay at this point in the year is unfortunate as tax loss harvesting season begins. the stock will bleed until data is released. how much it will bleed is anybody's guess. very disappointed by all these delays. it generally does not bode well. we shall see.
AZOZ
Posted - 6 days ago
$ATXI new position Armistice Capital, LLC loading 115k share https://fintel.io/so/us/atxi
omega42
Posted - 6 days ago
$ATXI my prediction is that there will be secondary as they are out of cash and then they announce AJ201 failure towards YE. As said, this one is bust.
hjg123
Posted - 6 days ago
$ATXI
“Topline data in Phase 1b/2a clinical trial of AJ201 for spinal and bulbar muscular atrophy anticipated around year-end 2024” “We are looking forward to sharing topline clinical data in the coming months”
From Q3 results right now.
hjg123
Posted - 6 days ago
$ATXI new positions filed today & yesterday;
Armistice capital / 115,000
UBS / 5,470 / total 6,143
Sabby management / 25,666 / total 63,060
Wells Fargo / 500 / total 561
zawojak
Posted - 6 days ago
$ATXI Most likely a bust
omega42
Posted - 6 days ago
$ATXI kind of disappointed with this one. we've been promised AJ201 results since Q2 and here we are with no update. most likely a bust.
Miguli80
Posted - 1 week ago
$ATXI waiting 4 rise
fortyfivezZ
Posted - 1 week ago
$ATXI rs incoming yet again
Newtothisting
Posted - 1 week ago
$ATXI all time lows incoming yet again
stockinvestbull
Posted - 1 week ago
$ATXI
hjg123
Posted - 1 week ago
$ATXI
Zellchair
Posted - 1 week ago
$FBIO Part 2 Then I valued all of these companies at $0: Cellvation - $0 Oncogenuity - $0 Avenue $ATXI - $0 Mustang $MBIO - $0 Comments: Is this then reasonable? Of course not. The contrasts of the top two against the bottom are telling here. FBIO has a high ownership stake in the first two but has not prioritized these as the overall opportunities for the entire business have been better in the near term elsewhere. In MBIO and ATXI there is low ownership and thus low risk, but with longer and proven assets that have shown fantastic data so far. Aevitas - $0.35 M Estimated: 10% chance of FDA approval where 4D-175 only reaches 25% of milestones/royalties. Comments: Not close to reasonable here either when 4D-175 is a combined drug where FDMT have already confirmed data. If 4D-175 succeeds, then presumably only the FDA approval will secure close to 25% in milestone directly on the day, without sales. And if you're mad now, I haven't even started...
ZUBI
Posted - 1 week ago
$ATXI Long @2.05
Newtothisting
Posted - 1 week ago
$ATXI ever gonna pop?
Cats_and_Roses
Posted - 1 week ago
$ATXI C'mon, it's earnings time. Give us some good news!
BiqwePower
Posted - 1 week ago
$ATXI
Zellchair
Posted - 1 week ago
$FBIO Part 2 CUTX-101 CUTX-10 reported positive topline clinical efficacy data showed a nearly 80% reduction in the risk of death (Hazard Ratio = 0.21, p<0.0001). No approved therapies exist for Menkes Disease globally. The only clinical competitor attempting to compete with CUTX-101 comes from the same subsidiary and uses CUTX-101 in combination with Gene Therapy. Triplex Triplex leading treatment for CMV control in HIV, SOT and HSCT recipients with better efficacy and superior safety profile compared to existing standard of care. Closest competitor generated $208 million, last reported quarter. AJ201 $ATXI AJ201 is the only drug that has shown that it can enhance mutant AR protein degradation and decreases neuroinflammation through its unique three-fold mechanism of action. No FDA approved therapies exist for SBMA patients, and AJ201 is the longest running in clinical studies.